Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Individualized adjuvant chemotherapy for surgically resected lung cancer and the roles of biomarkers.

Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia - 1 Jun 2009

Ikeda Norihiko, Nagase Seisuke, Ohira Tatsuo

Abstract excerpt

Several prospective randomized trials for patients with completely resected stages II and IIIA nonsmall cell lung cancer have confirmed a survival benefit with cisplatin-based adjuvant chemotherapy. The Lung Adjuvant Cisplatin Evaluation, which is based on pooled analyses of five randomized trials, has demonstrated a 4.2% absolute survival benefit at 5 years. The stage is the benchmark standard used to decide the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemotherapy, Adjuvant
Share to Cisplatin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Endonucleases

Share to Evidence-Based Medicine

Share to Patient Selection

Share to Pneumonectomy

Share to Randomized Controlled Trials as Topic

Share to Tubulin

Source

Identifiers

PMID: 19597387

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Individualized adjuvant chemotherapy for surgically resected lung cancer and the roles of biomarkers.PMID 19597387Read ↗

Personalized Therapy of Non-small Cell Lung Cancer (NSCLC).Semantic proximity Read ↗

Molecular pathogenesis of early-stage non-small cell lung cancer and a proposal for tissue banking to facilitate identification of new biomarkers.Semantic proximity Read ↗

Randomized Phase III Study of Cisplatin With Pemetrexed and Cisplatin With Vinorelbine for Completely Resected Nonsquamous Non-Small-Cell Lung Cancer: The JIPANG Study Protocol.Semantic proximity Read ↗

Biomarkers with predictive and prognostic function in non-small cell lung cancer: ready for prime time?Semantic proximity Read ↗

Integration of molecular profiling into the lung cancer clinic.Semantic proximity Read ↗

Risk Stratification and Adjuvant Chemotherapy Based on Clinical Risk Scores of Patients with Stage IB-IIA Non-Small Cell Lung CancerSemantic proximity Read ↗

The 5-year survival outcomes analysis of EGFR-TKI or/and chemotherapy as initial adjuvant therapy for completely resected IIIA non-small cell lung cancer.Semantic proximity Read ↗

Subgroup-Level Network Meta-Analysis for the Efficacy of First-Line Immunotherapy-Based Treatments in Advanced Non-Small Cell Lung CancerSemantic proximity Read ↗

Exploring adjuvant epidermal growth factor receptor inhibition in non-small cell lung cancer.Semantic proximity Read ↗

Current readings: Window-of-opportunity trials for thoracic malignancies.Semantic proximity Read ↗

Gene expression-based, individualized outcome prediction for surgically treated lung cancer patientsSemantic proximity Read ↗

Clinical Trials in Non-Small Cell Lung Cancer with Biomarker-Driven Treatment Allocation: Ready or Not, Here We Come.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.